secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2026-04-07T23:59:59+00:00
Accession:  0001493152-26-015445
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity Technologies' CyPath Lung featured at Cleveland Clinic symposium Apr 16
--------------------------------------------------------------------------------

- CyPath Lung test to be highlighted at invitation-only 'Advances in Early Lung Cancer Detection' symposium.
- CMO Gordon Downie, MD, PhD, to serve on panel discussing lung nodule management.
- Test has demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting early-stage lung cancer.
- This marks the company's seventh invitation to present at the Cleveland Clinic symposium.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226015445/0001493152-26-015445-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226015445/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-015445

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer